Fabrication and characterization of Raloxifene loaded Solid-lipid nanoparticles
AbstractPoor water solubility of the drug presents a great challenge for the formulation development and results in low oral bioavailability. The oral bioavailability of Raloxifene HCl (RLX) is very low (<2%) in human due to its poor solubility and extensive (>90%) first pass metabolism. To overcome these limitations, the present investigation deals with the development of Compritol 888 ATO based RLX-loaded solid lipid nanoparticles (SLNs) using oil in water microemulsion method. Drug-excipients compatibility was confirmed through FTIR spectroscopy, Differential scanning calorimetry. A total seventeen formulations (SLN1-SLN17) were developed as per the 3 level 3 factor Box–Bhenken design. The model used for the analysis were statistically analysed using ANOVA and the goodness of fit was evaluated using diagnostic plots. As per the response-surface plots, the amount of lipid, poloxamer 407 and ultrasonication time has significant effect on the particle size and entrapment efficiency (%EE). As per the desirability function value (0.959) the optimized formulation has the size and EE of 169.32 nm and 92.85%.
Keywords: Nanoparticles, drug delivery, raloxifene, solid-lipid nanoparticles, box–bhenken design
10 Views | Downloads
How to Cite
PANT, N. C., & JUYAL, V. (2021). Fabrication and characterization of Raloxifene loaded Solid-lipid nanoparticles . International Journal of Applied Pharmaceutics, 13(4). https://doi.org/10.22159/ijap.2021v13i4.41774
This work is licensed under a Creative Commons Attribution 4.0 International License.